FAM83A signaling induces epithelial-mesenchymal transition by the PI3K/AKT/Snail pathway in NSCLC
- PMID: 31444970
- PMCID: PMC6738414
- DOI: 10.18632/aging.102163
FAM83A signaling induces epithelial-mesenchymal transition by the PI3K/AKT/Snail pathway in NSCLC
Abstract
Family with sequence similarity 83, member A (FAM83A), as a potential tumor promoter, was reported to contribute to the progression of several malignant tumors. However, the significance of FAM83A in invasion and metastasis of non-small cell lung cancer (NSCLC) remains largely unknown. In this study, we found that FAM83A expression was significantly increased in NSCLC tissues. High expression of FAM83A was positively associated with tumor metastasis and poor survival of NSCLC patients. Functional experiments revealed that FAM83A knockdown could suppress NSCLC cell migration and invasion both in vivo and in vitro. While opposite results were observed in FAM83A-transfected cells. Mechanically, we found that FAM83A promoted NSCLC cell migration and invasion by inducing epithelial-mesenchymal transition (EMT) via PI3K/ATK/Snail signaling. Rescue experiment demonstrated that inhibition of either AKT or Snail could partially counteract the promoting effect of FAM83A overexpression in NSCLC metastasis. Taken together, our findings are the first time to demonstrate that increased expression of FAM83A in NSCLC was correlated with EMT and tumor metastasis, which may provide a novel therapeutic target in NSCLC treatment.
Keywords: EMT; FAM83A; non-small cell lung cancer.
Conflict of interest statement
Figures
Similar articles
-
Positive feedback loop of FAM83A/PI3K/AKT/c-Jun induces migration, invasion and metastasis in hepatocellular carcinoma.Biomed Pharmacother. 2020 Mar;123:109780. doi: 10.1016/j.biopha.2019.109780. Epub 2019 Dec 31. Biomed Pharmacother. 2020. PMID: 31901550
-
MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.Int J Oncol. 2017 Jul;51(1):235-244. doi: 10.3892/ijo.2017.3999. Epub 2017 May 16. Int J Oncol. 2017. PMID: 28534966
-
KIAA1199 promotes invasion and migration in non-small-cell lung cancer (NSCLC) via PI3K-Akt mediated EMT.J Mol Med (Berl). 2019 Jan;97(1):127-140. doi: 10.1007/s00109-018-1721-y. Epub 2018 Nov 26. J Mol Med (Berl). 2019. PMID: 30478628
-
[Current status of Akt in non-small cell lung cancer].Zhongguo Fei Ai Za Zhi. 2010 Nov;13(11):1059-63. doi: 10.3779/j.issn.1009-3419.2010.11.12. Zhongguo Fei Ai Za Zhi. 2010. PMID: 21081049 Free PMC article. Review. Chinese.
-
Autophagy-related signaling pathways in non-small cell lung cancer.Mol Cell Biochem. 2022 Feb;477(2):385-393. doi: 10.1007/s11010-021-04280-5. Epub 2021 Nov 10. Mol Cell Biochem. 2022. PMID: 34757567 Review.
Cited by
-
Carcinogenic Role and Clinical Significance of Histone H3-H4 Chaperone Anti-silencing Function 1 B (ASF1B) in Lung Adenocarcinoma.J Cancer. 2024 Jan 1;15(1):218-231. doi: 10.7150/jca.88777. eCollection 2024. J Cancer. 2024. PMID: 38164276 Free PMC article.
-
Circular RNA in Non-small Cell Lung Carcinoma: Identification of Targets and New Treatment Modalities.Cancer Genomics Proteomics. 2023 Dec;20(6suppl):646-668. doi: 10.21873/cgp.20413. Cancer Genomics Proteomics. 2023. PMID: 38035705 Free PMC article. Review.
-
APE1 promotes radiation resistance against radiation-induced pyroptosis by inhibiting the STING pathway in lung adenocarcinoma.Transl Oncol. 2023 Oct;36:101749. doi: 10.1016/j.tranon.2023.101749. Epub 2023 Aug 4. Transl Oncol. 2023. PMID: 37544034 Free PMC article.
-
Regulation of early diagnosis and prognostic markers of lung adenocarcinoma in immunity and hypoxia.Sci Rep. 2023 Apr 20;13(1):6459. doi: 10.1038/s41598-023-33404-8. Sci Rep. 2023. PMID: 37081097 Free PMC article.
-
Overexpression of FAM83A Is Associated with Poor Prognosis of Lung Adenocarcinoma.J Oncol. 2022 Oct 5;2022:8767333. doi: 10.1155/2022/8767333. eCollection 2022. J Oncol. 2022. PMID: 36245969 Free PMC article.
References
-
- Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, et al., and KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015; 372:2018–28. 10.1056/NEJMoa1501824 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
